The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial

Shirley Harvey Bush, Nathalie Lacaze-Masmonteil, Marie Theresa McNamara-Kilian, Alistair Richard MacDonald, Sallyanne Tierney, Franco Momoli, Meera Agar, David Christopher Currow, Peter Gerard Lawlor, Shirley Harvey Bush, Nathalie Lacaze-Masmonteil, Marie Theresa McNamara-Kilian, Alistair Richard MacDonald, Sallyanne Tierney, Franco Momoli, Meera Agar, David Christopher Currow, Peter Gerard Lawlor

Abstract

Background: Delirium is a very common and distressing neuropsychiatric syndrome in palliative care. Increasing age, the presence of dementia and advanced cancer are well-known predisposing risk factors for delirium development. Sleep-wake cycle disturbance is frequently seen during delirium and melatonin has a pivotal role in the regulation of circadian rhythms. Current evidence across various settings suggests a potential preventative role for melatonin in patients at risk of delirium, but no studies are currently reported in patients with advanced cancer. The aim of this article is to describe the design of a feasibility study that is being conducted to inform a larger randomized, placebo-controlled, double-blind trial (RCT) to evaluate the role of exogenously administered melatonin in preventing delirium in patients with advanced cancer.

Methods/design: Adult patients with a cancer diagnosis who are admitted to the palliative care unit will be randomized into a treatment or placebo group. The pharmacological intervention consists of a single daily dose of immediate-release melatonin (3 mg) at 21:00 ± 1 h, from day 1 to day 28 of admission. The primary objective of this initial study is to assess the feasibility of conducting the proposed RCT by testing recruitment and retention rates, appropriateness of study outcome measures, acceptability of study procedures and effectiveness of the blinding process. The primary outcome measure of the proposed larger RCT is time to first inpatient incident episode of delirium. We also plan to collect data on incident rates of delirium and patient-days of delirium, adjusting for length of admission.

Discussion: The outcomes of this feasibility study will provide information on recruitment and retention rates, protocol violation frequency, effectiveness of the blinding process, acceptability of the study procedures, and safety of the proposed intervention. This will inform the design of a fully powered randomized controlled trial to evaluate the preventative role of melatonin administration in patients with advanced cancer.

Trial registration: Registered with ClinicalTrials.gov: NCT02200172 Registered on 21 July 2014. Health Canada protocol number: BRI-MELAT-2013 (Final approved protocol version (Version 3): 18 June 2014) (Notice of Amended Authorization (NOA) received 14 November 2014).

Keywords: Advanced cancer; Delirium; Feasibility study; Melatonin; Pilot; Prevention; Randomized controlled trial (RCT); Sleep.

Figures

Fig. 1
Fig. 1
Overview of study design for melatonin feasibility study

References

    1. Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage. 1992;7:192–5. doi: 10.1016/0885-3924(92)90074-R.
    1. Lawlor PG, Bruera ED. Delirium in patients with advanced cancer. Hematol Oncol Clin North Am. 2002;16:701–14. doi: 10.1016/S0889-8588(02)00021-7.
    1. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer. 1997;79:835–42. doi: 10.1002/(SICI)1097-0142(19970215)79:4<835::AID-CNCR21>;2-#.
    1. Bush SH, Bruera E. The assessment and management of delirium in cancer patients. Oncologist. 2009;14:1039–49. doi: 10.1634/theoncologist.2009-0122.
    1. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry. 1983;140:1048–50. doi: 10.1176/ajp.140.8.1048.
    1. Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160:786–94. doi: 10.1001/archinte.160.6.786.
    1. Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage. 2001;22:997–1006. doi: 10.1016/S0885-3924(01)00360-8.
    1. Leonard M, Agar M, Mason C, Lawlor P. Delirium issues in palliative care settings. J Psychosom Res. 2008;65:289–98. doi: 10.1016/j.jpsychores.2008.05.018.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders: DSM-5. 5. Arlington: American Psychiatric Association; 2013.
    1. Dasgupta M, Hillier LM. Factors associated with prolonged delirium: a systematic review. Int Psychogeriatr. 2010;22:373–94. doi: 10.1017/S1041610209991517.
    1. Pautex S, Herrmann FR, Zulian GB. Factors associated with falls in patients with cancer hospitalized for palliative care. J Palliat Med. 2008;11:878–84. doi: 10.1089/jpm.2007.0241.
    1. Siddiqi N, House AO. Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35:350–64. doi: 10.1093/ageing/afl005.
    1. Balas MC, Happ MB, Yang W, Chelluri L, Richmond T. Outcomes associated with delirium in older patients in surgical ICUs. Chest. 2009;135:18–25. doi: 10.1378/chest.08-1456.
    1. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics. 2002;43:183–94. doi: 10.1176/appi.psy.43.3.183.
    1. Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y. Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics. 2004;45:107–13. doi: 10.1176/appi.psy.45.2.107.
    1. Bruera E, Bush SH, Willey J, Paraskevopoulos T, Li Z, Palmer JL, et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer. 2009;115:2004–12. doi: 10.1002/cncr.24215.
    1. Caraceni A, Nanni O, Maltoni M, Piva L, Indelli M, Arnoldi E, et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer. 2000;89:1145–9. doi: 10.1002/1097-0142(20000901)89:5<1145::AID-CNCR24>;2-X.
    1. O’Mahony R, Murthy L, Akunne A, Young J. Synopsis of the National Institute for Health and Clinical Excellence guideline for prevention of delirium. Ann Intern Med. 2011;154:746–51. doi: 10.7326/0003-4819-154-11-201106070-00006.
    1. Agar M, Lawlor P. Delirium in cancer patients: a focus on treatment-induced psychopathology. Curr Opin Oncol. 2008;20:360–6. doi: 10.1097/CCO.0b013e328302167d.
    1. Lawlor PG, Fainsinger RL, Bruera ED. Delirium at the end of life: critical issues in clinical practice and research. JAMA. 2000;284:2427–9. doi: 10.1001/jama.284.19.2427.
    1. Bourne RS, Tahir TA, Borthwick M, Sampson EL. Drug treatment of delirium: past, present and future. J Psychosom Res. 2008;65:273–82. doi: 10.1016/j.jpsychores.2008.05.025.
    1. Gagnon P, Allard P, Gagnon B, Merette C, Tardif F. Delirium prevention in terminal cancer: assessment of a multicomponent intervention. Psychooncology. 2012;21:187–94. doi: 10.1002/pon.1881.
    1. Inouye SK, Bogardus ST, Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340:669–76. doi: 10.1056/NEJM199903043400901.
    1. Siddiqi N, Stockdale R, Britton AM, Holmes J. Interventions for preventing delirium in hospitalised patients. Cochrane Database Syst Rev. 2007;4:CD005563.
    1. Tabet N, Howard R. Pharmacological treatment for the prevention of delirium: review of current evidence. Int J Geriatr Psychiatry. 2009;24:1037–44. doi: 10.1002/gps.2220.
    1. Canadian Coalition for Seniors’ Mental Health. Guideline on the assessment and treatment of delirium in older adults at the end of life. . Accessed 22 Jan 2016.
    1. Meagher DJ, Moran M, Raju B, Gibbons D, Donnelly S, Saunders J, et al. Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br J Psychiatry. 2007;190:135–41. doi: 10.1192/bjp.bp.106.023911.
    1. Bosisio M, Caraceni A, Grassi L. Phenomenology of delirium in cancer patients, as described by the Memorial Delirium Assessment Scale (MDAS) and the Delirium Rating Scale (DRS) Psychosomatics. 2006;47:471–8. doi: 10.1176/appi.psy.47.6.471.
    1. de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry. 2010;25:1201–8. doi: 10.1002/gps.2454.
    1. Meagher D. Motor subtypes of delirium: past, present and future. Int Rev Psychiatry. 2009;21:59–73. doi: 10.1080/09540260802675460.
    1. Fitzgerald JM, Adamis D, Trzepacz PT, O’Regan N, Timmons S, Dunne C, et al. Delirium: a disturbance of circadian integrity? Med Hypotheses. 2013;81:568–76. doi: 10.1016/j.mehy.2013.06.032.
    1. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186–95. doi: 10.1056/NEJM199701163360306.
    1. Maestroni GJ. The immunoneuroendocrine role of melatonin. J Pineal Res. 1993;14:1–10. doi: 10.1111/j.1600-079X.1993.tb00478.x.
    1. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008;7:189–203. doi: 10.1177/1534735408322846.
    1. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer. 2002;10:110–6. doi: 10.1007/s005200100281.
    1. Mahmoud F, Sarhill N, Mazurczak MA. The therapeutic application of melatonin in supportive care and palliative medicine. Am J Hosp Palliat Care. 2005;22:295–309. doi: 10.1177/104990910502200412.
    1. Bourne RS, Mills GH. Melatonin: possible implications for the postoperative and critically ill patient. Intensive Care Med. 2006;32:371–9. doi: 10.1007/s00134-005-0061-x.
    1. Magri F, Sarra S, Cinchetti W, Guazzoni V, Fioravanti M, Cravello L, et al. Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res. 2004;36:256–61. doi: 10.1111/j.1600-079X.2004.00125.x.
    1. Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010;48:142–7. doi: 10.1111/j.1600-079X.2009.00737.x.
    1. Balan S, Leibovitz A, Zila SO, Ruth M, Chana W, Yassica B, et al. The relation between the clinical subtypes of delirium and the urinary level of 6-SMT. J Neuropsychiatry Clin Neurosci. 2003;15:363–6. doi: 10.1176/jnp.15.3.363.
    1. Maldonado JR. Neuropathogenesis of delirium: review of current etiologic theories and common pathways. Am J Geriatr Psychiatry. 2013;21:1190–222. doi: 10.1016/j.jagp.2013.09.005.
    1. de Rooij SE, van Munster BC. Melatonin deficiency hypothesis in delirium: a synthesis of current evidence. Rejuvenation Res. 2013;16:273–8. doi: 10.1089/rej.2012.1405.
    1. Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71:397–403. doi: 10.1001/jamapsychiatry.2013.3320.
    1. Miyazaki T, Kuwano H, Kato H, Ando H, Kimura H, Inose T, et al. Correlation between serum melatonin circadian rhythm and intensive care unit psychosis after thoracic esophagectomy. Surgery. 2003;133:662–8. doi: 10.1067/msy.2003.149.
    1. Olofsson K, Alling C, Lundberg D, Malmros C. Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand. 2004;48:679–84. doi: 10.1111/j.0001-5172.2004.00401.x.
    1. Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2011;26:687–94. doi: 10.1002/gps.2582.
    1. Chen S, Shi L, Liang F, Xu L, Desislava D, Wu Q et al. Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials. Mol Neurobiol. 2016;53(6):4046-53. doi:10.1007/s12035-015-9350-8. Epub 2015 Jul 21.
    1. Jansen SL, Forbes D, Duncan V, Morgan DG, Malouf R. Melatonin for the treatment of dementia. Cochrane Database Syst Rev. 2006
    1. Bjorvatn B, Pallesen S. A practical approach to circadian rhythm sleep disorders. Sleep Med Rev. 2009;13:47–60. doi: 10.1016/j.smrv.2008.04.009.
    1. Karasek M. Does melatonin play a role in aging processes? J Physiol Pharmacol. 2007;58(Suppl 6):105–13.
    1. Hagen NA, Biondo PD, Brasher PMA, Stiles CR. Formal feasibility studies in palliative care: why they are important and how to conduct them. J Pain Symptom Manage. 2011;42:278–89. doi: 10.1016/j.jpainsymman.2010.11.015.
    1. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002
    1. Whitehead AL, Sully BG, Campbell MJ. Pilot and feasibility studies: is there a difference from each other and from a randomised controlled trial? Contemp Clin Trials. 2014;38:130–3. doi: 10.1016/j.cct.2014.04.001.
    1. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10:1. doi:10.1186/1471-2288-10-1.
    1. Hosie A, Davidson PM, Agar M, Sanderson CR, Phillips J. Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: a systematic review. Palliat Med. 2013;27:486–98. doi: 10.1177/0269216312457214.
    1. STATA Data Analysis and Statistical Software. [14.1]. Texas: StataCorp LP; 2016.
    1. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care. 1996;12:5–11.
    1. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113:941–8. doi: 10.7326/0003-4819-113-12-941.
    1. Gagnon P, Allard P, Mâsse B, DeSerres M. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage. 2000;19:412–26. doi: 10.1016/S0885-3924(00)00143-3.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;140:734–9. doi: 10.1176/ajp.140.6.734.
    1. Fainsinger RL, Nekolaichuk C, Lawlor P, Hagen N, Bercovitch M, Fisch M, et al. An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer. 2010;46:2896–904. doi: 10.1016/j.ejca.2010.04.017.
    1. Watanabe SM, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F. A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage. 2011;41:456–68. doi: 10.1016/j.jpainsymman.2010.04.020.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. doi: 10.1016/0021-9681(87)90171-8.
    1. Bastien C. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. doi: 10.1016/S1389-9457(00)00065-4.
    1. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997;13:128–37. doi: 10.1016/S0885-3924(96)00316-8.
    1. U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). (v4.03: June 14, 2010). 2010. . Accessed 22 Jan 2016.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe